Therefore, targeting the A1/A2 astrocytic balance and enhancing BDNF signaling within astrocytes provide a promising therapeutic strategy for treating major depressive disorder and other conditions where neuroplasticity is impaired. This evidence concerns the gene BDNF and major depressive disorder.